J.B.Chemicals & Pharmaceuticals Ltd. (BSE: 506943) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹0 Cr, it ranks #5,551 by market cap among the 6,197 Indian listed companies on FinBizNet, and #85 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,416.10 (as of 16 Nov 2026), the share price is 4.3% below its 52-week high of ₹2,525.50 and 1.5% above its 52-week low of ₹2,380.00. The share price is up 43.0% over one year and up 17.9% over three months.
| Current Price | ₹2,416.10 |
|---|---|
| Market Cap | ₹0 Cr |
| BSE Code | 506943 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| Return on Equity | 18.69% |
| Return on Assets | 12.48% |
| 52-Week Range | ₹2,380.00 – ₹2,525.50 |
| 1-Year Price Change | +43.0% |
| 3-Month Price Change | +17.9% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.jbpharma.com |
| Revenue | ₹904 Cr |
|---|---|
| Net Profit | ₹101 Cr |
| Net Margin | 11.2% |
| EPS (Basic) | ₹6.35 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
J.B.Chemicals & Pharmaceuticals Ltd. reported revenue of ₹904 Cr in Q4 FY26, down 4.8% from ₹949 Cr in Q4 FY25 and down 15.1% from ₹1,065 Cr in Q3 FY26. It posted a net profit of ₹101 Cr for the quarter, against a net profit of ₹146 Cr in Q4 FY25 (down 30.4%). Across the 5 quarters from Q4 FY25 to Q4 FY26, quarterly revenue ranged from ₹904 Cr (Q4 FY26) to ₹1,094 Cr (Q1 FY26). The company was profitable in each of these 5 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q4 FY26 | ₹904 Cr | ₹101 Cr | 11.2% |
| Q3 FY26 | ₹1,065 Cr | ₹198 Cr | 18.6% |
| Q2 FY26 | ₹1,085 Cr | ₹208 Cr | 19.2% |
| Q1 FY26 | ₹1,094 Cr | ₹202 Cr | 18.5% |
| Q4 FY25 | ₹949 Cr | ₹146 Cr | 15.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 48.80% of J.B.Chemicals & Pharmaceuticals Ltd.'s shares as of Mar 2026, against 47.73% in Jun 2025 (+1.07 percentage points).
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-anal
1. Pharmaceuticals-This segment manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| J.B.Chemicals & Pharmaceuticals Ltd. | ₹0 Cr | — | 18.69% | ₹904 Cr | +43.0% |
Listed by market capitalisation. Ratios are shown for context only.
J.B.Chemicals & Pharmaceuticals Ltd. is trading at ₹2,416.10, with a market capitalisation of ₹0 Cr.
J.B.Chemicals & Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
J.B.Chemicals & Pharmaceuticals Ltd. has a return on equity of 18.69%.
J.B.Chemicals & Pharmaceuticals Ltd. is listed on the BSE under the scrip code 506943.
J.B.Chemicals & Pharmaceuticals Ltd.'s share price is up 43.0% over one year and up 17.9% over three months. Its 52-week range is ₹2,380.00 to ₹2,525.50.
In Q4 FY26, J.B.Chemicals & Pharmaceuticals Ltd. reported revenue of ₹904 Cr and net profit of ₹101 Cr, with basic EPS of ₹6.35 (consolidated, parsed from the company's exchange filing).
J.B.Chemicals & Pharmaceuticals Ltd. reported revenue of ₹904 Cr in Q4 FY26, down 4.8% from ₹949 Cr in Q4 FY25 and down 15.1% from ₹1,065 Cr in Q3 FY26.
Promoters held 48.80% of J.B.Chemicals & Pharmaceuticals Ltd.'s shares as of Mar 2026, against 47.73% in Jun 2025 (+1.07 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.